Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Medical Science Monitor

Volumn 17, Issue 4, 2011, Pages 1-13

  Orlewska, Ewa ^a   Ancuta, Ioan ^b   Anic, Branimir ^c   Codrenau, Catalin ^d   Damjanov, Nemanja ^e   Djukic, Predrag ^f   Ionescu, Ruxandra ^g   Marinchev, Lubomir ^h   Nasonov, Evgeny L ⁱ   Peets, Tonu ^j   Praprotnik, Sonja ^k   Rashkov, Rasho ^h   Skoupa, Jana ^l   Tlustochowicz, Witold ^m   Tlustochowicz, Malgorzata ^m   Tomsic, Matija ^k   Veldi, Tiina ⁿ   Vojinovic, Jelena ^f   Wiland, Piotr ^o  

^a Centre for Pharmacoeconomics   (Poland)

^b Clinical Institute Ion Catacuzino   (Romania)

^c KBC Zagreb   (Croatia)

^d Methodical Rheumatology Center Prof Dr Ion Stoia   (Romania)

^e Institute of Rheumathology   (Serbia)

^f Consultant for Health Economics and Management ^*  (Serbia)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

ⁱ V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^j East Tallinn Central Hospital   (Estonia)

^k UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^l Pharma Projects sro   (Czech Republic)

^m MILITARY INSTITUTE OF MEDICINE   (Poland)

ⁿ East Tallin Central Hospital   (Estonia)

^o WROCLAW MEDICAL UNIVERSITY   (Poland)

more..

Author keywords

Biologic treatment; Guideline; Health services accessibility; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CHLOROQUINE; CYCLOSPORIN; ETANERCEPT; GOLD SALT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ARTICLE; COST OF ILLNESS; DISEASE ACTIVITY; DRUG COST; EUROPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; PRESCRIPTION; QUESTIONNAIRE; REIMBURSEMENT; RHEUMATOID ARTHRITIS; TREATMENT FAILURE;

EID: 79953703985     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881697     Document Type: Article

References (31)

1. Sokka T, Kautiainen H, Pincus T et al: Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis, 2009; 68(11): 1666-72
2. Hanova P, Pavelka K, Dostal C et al: Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol, 2006; 24(4): 499-507
3. Otsa K, Tammaru M, Vorobjov S et al: The prevalence of rheumatoid arthritis (RA) in Harju County, Estonia. EULAR 2009; Abstract FRI0517
4. Kiss CG, Lovei C, Suto G et al: Prevalence of rheumatoid arthritis in the South-Transdanubian region of Hungary based on a representative survey of 10,000 inhabitants. J Rheumatol, 2005; 32(9): 1688-90
5. Péntek M, Kobelt G, Czirják L et al: Costs of rheumatoid arthritis in Hungary. J Rheumatol, 2007; 34(6): 1437-38
6. Jankovic S, Kostic M, Radosavljevic M, Jovanovic S: Cost of rheumatoid arthritis in a Balcan Country (Serbia). East European Politics& Societes, http://eep.sagepub.com
7. Guillemin F, Durieux S, Daurés JP et al: Costs of rheumatoid arthritis in France: A multicenter study of 1109 patients managed by hospitalbased rheumatologists. J Rheumatol, 2004; 31: 1297-304
8. Verstappen SM, Verkleij H, Bijlsma JW et al: Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis, 2004; 63: 817-24
9. Westhovens R, Boonen A, Verbruggen L et al: Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol, 2005; 24: 615-19
10. Hulsemann JL, Ruof J, Zeidler H, Mittendorf T: Costs in rheumatology: results and lessons learned from "Hannover Costing Study". Rheumatol Int, 2006; 26: 704-11
11. NHF Resolution No 52/15/2008, 16. Oct 2008, concerning reimbursement of etanercept (Enbrel), adalimumab (Humira) and infliximab (Remicade) within the framework of therapeutic programme: "Treatment of rheumatoid arthritis " (in Polish) http://www.aotm.gov.pl/assets/files/ rada/uchwala_rk_aotm_52_15_2008_etanercept_Enbrel_adalimumab_Humira_ infliksimab_Remicade.pdf
12. Kaczor M, Wójcik R: An economic analysis of TNF-alpha anatgonists for rheumatoid arthritis. (Polish) Reumatologia, 2007; 5: 268-75 (in Polish)
13. Brodszky V, Péntek M, Májer I et al: Economic evaluation of the first TNF-alpha inhibitor therapy in patients with rheumatoid arthritis. Technology Assessment Report September 2007, http://hecon.uni-corvinus. hu/download/english/publ/hecon_research_23_eng.pdf
14. Májer I, Péntek M, Brodszky V, Gulácsi L: Health economics modelling: cost, effectiveness and cost-effectiveness of biological agents in patients with rheumatoid arthritis with particular emphasis on infliximab (Remicade) therapy. Technology Assessment Report June 2006. http://hecon.uni-corvinus.hu/download/english/publ/hecon_research_19.pdf
15. Brodszky V, Péntek M, Májer I et al: Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation. Technology Assessment Report June 2007. http://hecon.uni-corvinus.hu/download/ english/publ/hecon_research_22_eng.pdf
16. Brodszky V, Péntek M, Kárpáti K et al: Economic evaluation of rituximab in the treatment of rheumatoid arthritis in Hungary. Farmakoekonomika, 2008; 12(1): 10-16
17. Tan-Torres Edejer T et al: Choosing intervention that are cost-effective (WHO-CHOICE), 2003
18. Ansuta I, Baculea S, Szkultecka-Debek M: Cost-effectiveness evaluation of tocilizumab in Romanian health care system. Management in Health, 2009; 3: 7-10
19. NHIF requirements concerning protocols for rheumatoid arthritis treatment with rituximab (in Bulgarian). http://www.nhif.bg/downloads/ iziskvania_RA_Rituximab-21-09-09.doc
20. NHIF requirements concerning protocols for rheumatoid arthritis, psoriatic arthritis and juvenile arthritis treatment with anti-cytokine drugs: adalimumab, etanercept (in Bulgarian). http://www.nhif.bg/downloads/ iziskvania_Revmatoiden_artrit_anticitokini-01-09-09.doc
21. Bečvář R, Vencovský J, Němec P et al: Recommendations of Czech Rheumatological Association for the treatment of rheumatoid arthritis. Efficacy and treatment strategies. Čes revmatologie, Praha, 2007; 15(2): 73-90 (in Czech)
22. Čurković, B, Babić-Naglić D{stroke}, Morović-Vergles J et al: Proposal for antiTNFalpha therapy in adult patients with rheumatoid arthritis. Reumatizam, 2007; 54(1): 16-19 (in Croatian)
23. Estonian Health Insurance Fund List, www. riigiteataja.ee/ert/act. jsp?id=13231527
24. The professional protocol of the Ministry of Health on the use of biological therapy in inflammatory rheumatological diseases. Egészségügyi Közlöny, 2008; 9: 2811-46 (in Hungarian)
25. Therapeutic Health Programme 2009. Treatment of rheumatoid arthritis and juvenile arthritis with aggressive progression. Attachment No 13 to Regulation of NHF Director from Sept 15, 2009 (in Polish). http:// www.nfz-krakow.pl/UserFiles/Leczenie%20RZS%20i%20MIZS.pdf
26. NHI order approving the protocol of practice on prescribing, monitoring and settlement drugs for insured RA patients (in Romanian). http://www.cnas.ro/pdf/ordin221mai07.pdf
27. Damjanov N, Vojnović J: Biologic therapy of rheumatoid arthritis. Srpski arhiv za celokupno lekarstvo, 2009; 137(3-4): 205-10 (in Serbian)
28. Rovensky J, Rybar I, Mičekova D et al: Pharmacotherapeutic approaches for rheumatoid arthritis. Via pract, 2005; 2(2): 66-74 (in Slovakian)
29. Ministry of Health Regulation on Disease activity and joint function impairment assessment in patients with RA (in Slovakian). http://www. health.gov.sk/redsys/rsi.nsf/0/298af39beb3c4a18c12575d2003305d6/$FILE/ vestnik_25_2009.pdf
30. Kobelt G, Kasteng F: Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). October 2009. http://www. lif.se/cs/Publik%20webb/Sidinnehall/Publik_Dokument/Pressmeddelanden/ Access%20to%20RA%20Treatments%20October%202009.pdf
31. Jönsson B, Kobelt G, Smolen J: The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ, 2008; 8(Suppl.2): S33-106